ALK/ROS1 Inhibitor XZP-3621 clinical trials
Also written XZP-3621.
How each study uses ALK/ROS1 Inhibitor XZP-3621 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ALK/ROS1 Inhibitor XZP-3621 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- XZP-3621
- 4
Studies by the year they started
6 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ALK/ROS1 Inhibitor XZP-3621 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCNot yet recruitingPhase 2Xuanzhu Biopharmaceutical Co., Ltd.NCT05482087Written as XZP-3621
- A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus CrizotinibNot yet recruitingPhase 3Xuanzhu Biopharmaceutical Co., Ltd.NCT05204628Written as XZP-3621
- A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung CancerCompletedPhase 1Xuanzhu Biopharmaceutical Co., Ltd.NCT05055232Written as XZP-3621
- Food Effect and Mass Balance Study of XZP-3621 TabletsCompletedPhase 1Xuanzhu Biopharmaceutical Co., Ltd.NCT05034120Written as XZP-3621
- A Study of the Absorption, Metabolism and Excretion of [14C]XZP-3621 in HumanStatus unknownPhase 1Xuanzhu Biopharmaceutical Co., Ltd.NCT05836805Written as [14C]XZP-3621
- Drug-drug Interaction Study of XZP-3621 TabletStatus unknownPhase 1Xuanzhu Biopharmaceutical Co., Ltd.NCT05586568Written as XZP-3621 tablet and Rifampicin capsules (For Arm 2)